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The interaction of CD28 with B7 molecules (CD80 or
CD86) is an essential second signal for both the
activation ofCD4+ T cells through the T-cell recep-
tor and the prevention of anergy. We studied the
requirement of hapten-specific human CD8+ cells
for CD28 co-stimulation in recognition of hapten,
and anergy induction. Urushiol, the immunogenic
hapten of poison ivy (Toxicodel/dl'Oll mdical/s), elicits a
predominantly CD8+ T-cell response. Autologous
PBMC were pre-incubated with urushiol prior to
fixation by paraformaldehyde. Fixed antigen-pre-
senting cells were unable to present urushiol to hu-
Inan CD8+ urushiol-specific T cells. Addition of
anti-CD28, however, overcame this antigen-present-
ing defect, enabling CD8+ cells to proliferate. Fixa-
tion of antigen-presenting cells prevents upregula-
tion of B7, and addition of anti-CD28 substitutes for
P resentation of antigen to T lymphocytes involves theinteractions of multiple adhesion molecules, and T-cellreceptor occupancy is not sufficient co induce T-cellproliferation. Interaction of CD4 + T cells with antigenin the absence of such appropl'iate co-stimulatory sig-
nals can induce tolerance Oenkins and Schwartz, 1.987; Quill and
Schwartz. 1987). The interaction of CD28 and B7-1. (CD80) or
B7-2 (CD86) has been shown to deliver such an essential co-
stimulatory signal to both human (Giml11 el nl, 1991; Jenkins el nl,
1991; Young 1'1 nl, 1992; Freeman 1'1 nl, 1993a) and murine (Gross
el nl, 1992; Harding 1'1 (/1, 1992; Freeman el nl, '\993b; Hathcock 1'1
(/1, 1993) CD4+ T cells.
CD28 is a T-cell antigen, and 137-1 is an inducible antigen of
antigen- prescnting cells (APC) and T cells. CD28 is expressed on
most if not all CD4+ T cells, but only 50% of CDS+ T cells
(Damlc ef nl, '1983). The proliferative response of CDS + cells to
minor transplantation antigen (Tan l'I (/1, '\992) and the generation
of CD8 + cytotoxic effectors (Tan er (/1. 1993) can be suppressed by
blocking CD28. CD28 blocking reagents such as CTLA41g are thus
of considerable interest for possible use ill immunotherapy (Len-
show el nl, '\992; Schwartz, 1992). This study investigates the role
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this signal. Proliferation of CD8+ T cells in response
to urushiol was blocked by CTLA4Ig, a recombinant
fusion protein that blocks CD28/B7 interactions. Pre-
incubation of urushiol-specific CD8+ cells with fixed
PBMC + urushiol for 7 d induced anergy. Anergic
CD8+ cells were viable and able to proliferate in
response to IL-2, but not in response to urushiol.
Induction of anergy required the presence of uru-
shiol, and pre-incubation with irradiated PBMC +
urushiol did not have this effect. It is proposed that
anergy was induced by presentation of urushiol by
fixed PBMC, in the absence of adequate co-stitnula-
tion signals. Induction of anergy by blocking of
co-stimulation could potentially induce clinical hy-
posensitization to haptens. Key lVo"ds: attel'gJl/co-sti",JI-
latol')' molecules/al/tige" p,·ese"tatio". ] I"vest Del'lltatol
108:253-257, 1997
of co-stimulation by CD28 in the human CD8+ response to the
hapten urushiol, as well as the effect of absence of such co-
stimulation on the induction of hapten-specific anergy.
Urushiol is the immunogenic component of poison ivy (Toxico-
del/drol/ rndicnl/s) resin (Dawson, 1956; Byck and Dawson, 1968;
Baer, 1986). Urushiol can be processed by the endogenous pathway
(Kalish el nl, 1994), ;lI1d a lal'ge proportion of the human response
to urushiol is mediated by CI 8+ T cells (Kalish ;lI1d Morimoto.
1988. 1989; Kalish and Johnson 1990).
Anti-CD28 has been shown to reconstitute the response of
CD4+ T cells to tetanus toxoid presented by fixed APC Oenkins et
nl, '\991). Addition ofanti-CD28 substitutes for the inability of dead
fixed APC to upregulate B7-1. Similar experiments were per-
formed to determine whether anti-CD28 could also reconstitute
the ability of human CD8+ T cells to recognize urushiol presentcd
by APC fixed with paraformaldehyde. It was found that anti-CD28
supplied a necessary co-stimulation signal tor the proliferation of
CD8+ T cclls in response to urushiol. Furthermore. urushiol-
specific anergy was induced by pre-incubation ofCD8+ urushiol-
specific T cells with fixed pCJ'ipheral blood mononuclear cells
(PBMC) + urushiol. It is proposed that anergy results fi'ol11
presentation of urushiol in the absence of a full complement of
accessory signals. illcluding B7/CD28. Inhibition of CD28/B7
co-stimulation is a potential method for clinical hyposensitization of
both CDS+ and CD4+ T cells.
MATEKIALS AND METHODS
Antigens Purificd urushiol was the generous gift of Dr. H. Baer of thc
Burcau of Biologics. Food and Drug Administration (Bethesda. MO).
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Ana.lysis of the purified urushiol by !las chro ll1acog.raphy showed no 
saturated side cbains and a minimu m of 95'% catechol (Dr. Bacr, personal 
COflln)uni cation). T he 11 1 .. \ f.c ri a I w'as 85.1 %, C l S tricnc, 10.2'Yo COJTlbillation 
lUo no- ajld dienc , alJd 4.7% C17 rrielle. Urllshiol was used in cell cul tme at 
a conccntration of J .O l.Lg pcr ml, which waS previously fO lmd to give 
oprimal T-ce ll proliferation (KaJish el <II , 1994) 
Anti-CD28 and CTLA4Ig Murllle monoclonal anti- hurnan CD 28 
(4E IO) .vas obtaincd f.·om Dr. Chikao Morimoto (Dana-F;lrbcr Cnncee 
IlI sritut' , .I3oston, MA). CTLA4Ig, a recombinant molecule for.mcd by 
fusion (If the extracellular dOlllain. of CTLA-4 and JgG (Limlcy d ai , 1991) 
was obtajned from I r. Perer Lins ley (Bristo l-Mye rs Sq uibb Ph"rmaccuric<ll 
R esearch Institu te, Seattle, W A). I.e is capable of blocking tbe interaction of 
B7 with CD 28 on human T ce lls (Sch",,,rtz, 1992; Lens},ow, 1992). 
GeneratiOtl of Shor t Term Human T - Cell Lines Responsive to 
Urushiol PBNlC were i.<o)ated from hcporillized blood by ccntrifug<ltion 
over Fico ll / Hypaquc (Pbannacia, f'isc<lwway, NJ). PJJMC were suspcnd<:d 
with urushiol (1 l.Lg per. rlll) at "[ X ·10" celJ s peT 1111 in AIM V llledilU11 
(GlBCO, Gr·and Island , NY) and plated .1.0 1'11 1 pcr weU in 24-well plates. 
Starring Oll day 5, medium was changed every 3-4 d with AIM V media 
conraining rc 'o l1lbinant interJ cukin-2 (I L-2) (5 U per mJ; .I3oehringer-
Mmlj1heim, indianapolis, IN) . T-cell lines were used fot experiments 2 to 4 
w k fo llowing initi"tioll of Gultures. All T-cell lines were derived from tlle 
same dOIlQr selected for strong ;11 ,,;1.-0 respollse to lIrush.iol. 
Isolation of CD8+ by Negative Selection on Anti-CD4-Coated 
Flasks T cel.ls were fir·st iso lated from short-term T-cell lines by E-
rosetting (.K:lljsh "' oJ, 19!18). C DB + were purified ITom th 'se T cells by 
negative selection foJJ owing adherencc to anti-CD4-cO:ltcd 25-cm2 tlasks 
(AIS NlicroCelicctor; Applied Immllne Scien ces Inc, Menlo Park, CA ). T 
cells were washed with PBS and resuspended ,It 5 X 1 () " cells per rn l in Pl.lS 
conta iJlin g 1 mM EDT A and 0.5'% human 'Y-globulin (Sigma, St LOlli s MO). 
Afte r re-hydrating the T-25 culture An sk as per directions, 4 1111 (20 X JO") 
cultured T cells were ,lddcd .md incubated ;It 25°C for 1 h . Negatively 
selected , nonadhercllt cells were then ge lltly decanted, """shed twice, '1Jld 
resuspended in A1M V media (GJECO). 
Preparatioll of APC P13M C jsolated ftom peripheral blood by celltrif-
uga l~O"II over Fico lllHypaq Lle (Ph, .... 'Jacia) were used as AI'C. PBMC were 
cryoprescrvcd w ith J 0%. dimethylsulfoxide and thawed on the day of the 
e>qJerimem . P.I3M G Werc pre-in ·"bated with urushiol ( 1.0 JLg per ml) "'" 
37°C for ·1 h and either irradiated 6.000 It (cesium source) or fixed with 
parafomlaldchyde .~ s detailed below. Control P.I3M C WL!re not exposed to 
urushio l. 
ParaCorma ldehyde Fixation of APC Followi ng pre-incubation with 
mushio.1 (above), APC were fixed in 0. 12% pa.raformaldehydc as previously 
described (Kalish e( ai, 1994). Freshly prcp;lr(~d pilraformaldehydc was added 
to APC (1 .0 ml to a pellct of 1.5 X .j 06 c.ells in a 5-ml cube) for a 5-lllin 
incubatioll at 2s"C. lll cllb;rtioll was stopped by the addjtion of 4.0 1111 of 
glycjne bulfer (0 .15 M. pH 7.4) follow ed by three wa, hes with SMEM 
containing 2.5% newborn c,lIf sc rull1. APC were then resuspended in 0.6 ml 
of AIM V mcdium. 
T-Cell Proliferation Assays C ultured C D8+ T cells were washed 
twice aud incub<1ted at 37°C for 2 h in SME.M 2.5% newborn calf serum 
prior to a fiv :rl wasb, "fter which they were rcs lI.\pendcd at 5 X :l 0' ce lls per 
lUI in AIM V medium. T cell s (0.1 Ill!) were added to APC (0.1 ml) in 
96-wcll U-bottoJ11 plates for a [ota l vo lum e of 0.2 1111 pcr well. R.eplic'HcS 
of six wells wer.e used for each treatment group. ·W hen il1dic;rted, anti-
0 28 :Iscites (4.JJ10) was added to the wells ;It a fin,, ) di lution of 1 :500. 
Wells were pulsed with eHltlr Yl11id ine (1 uC i/wcll; N EN/ Duponc, .JJoston, 
MA) at 24 h, harvested 18 h lilter, '/Ild counted with a liqu id sc.intillatio n 
counter (LKJ3, Gaithersburg, MD). 
Cytofluorogcaph Analysis of Cell P h enotype T-ce ll lines were phc-
nOl) lpcd fo llowjng immunoflu orescence stainin g with anti-CD3 (H. .. W2-
8C8; 19G ,) , anti-CD4 ( 1.9ThySD7; IgG 2), Hnd ;lll ti-CD8 (7PT3P9; IgG2 ; 
antl-CD21:l (413"10) (above antibodies obta ined from Dr. C lr.ikao Morimoto, 
Dana-Farber Cancer Institute). ~'.Il ti-Cj)2 (Tl 1; Coultcr, l-kde:lh, FL), 
allti-B1 (Coulter), anti-M O l (Coul ter), and allti-TC Il..-ddtal (T-ce ll Sci-
ences, Woburn, MA) fo llowed by gOllt anll-lTIO ll se F ITC (Sigma. St. Louis, 
M O ). M o use IgG (Coulter) was used as a nega tive con ~ro l. T he ,mal)'sis was 
performed by the flow cytometry fa cility at SUNY Stony Brook using a 
FA CSTAR PLUS (Becton Dickinson, S'"1 Jose. C Al. Nonviabl e cells were 
gated out by forward and side-sc;,tter, along with propidiullI iodide staining. 
Induction of Anergy of CD8+ Urushiol-Specific Human T Cells 
C D8 + celJs were purified by p;lI1ning (AJS f1asks) frol11 a urushiol-specific 
human T-cell line. T he CD 8+ cells ("1 .5 X 106 pcr tube) were cultured for 
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7 d with APe (1.5 X 10" per tube, rota I vo lunre 3.0 ml) ill ' I 5-ml tiss ll e 
culture tube ( :!: ) urushio l. Both frxcd P13M C and irradia ted P13M C were 
used as A PC. Medium ror in cub"rioll COl/ wi lled 5 U of I L-2 per J111 
(lJoehringcr-M;lIlnhcim). After 7 d of incubnrion , eile C OIo: + ce lls Wet\! 
wa5hcd and cCl unced wlth rryp,lll blue for viabi li ty. CD8 + ce ll s wen~ tb en 
added to a prolife ration assa), :IS dcscr-ibed above, along with fr., sh irrad.i :lted 
alltologolls PEM C as APC. 
RESULTS 
Generati.oll and Phenotyping of Human Ucusl1iol Respon_ 
sive T-Cell L ines U sing the procedure descri bed abo ve , sh ort_ 
term hurmln T-cell lines w e l·c gen crated in respo nse to uru sh.i ol. 
Two weeks after initiati o n of c llltll(eS, t he T ce lls were jJuritlcd bv 
sheep erythrocyte rosetting and phe llotyp d for expression of C D 3 . 
CD4, CDS, CD28, and "1/ 8 T - cell receptor. Urushio l-respo nsiv e 
lines were predominantly C D3 + CD8 + . T his was complltibJe with 
our prcviously publishe d re ports O ll urushi o l-spe ifi e T-ce ll lines 
and clones (Ka lish el ai, 1994; Ka lish and M.o rim oto, 1988, 1989; 
Kalish and John son , j 990) . Prcfel·e rHia l g rowth o f CD8 + T ceUs 
wa s not a ll artifac t of the cllJtllre conditions, in ;lsmu ch as tetanus 
toxoid-spec ific lines gen erated £i-om th ' same donor were 
CD4+CD8 - (Ka lish cl <1 /, 1994). Afte r purification by sheep red 
blood cell s rosetting, T- el l lin es showed levels of staining below 
background (1. %) w ith marke rs for rrtac rophages (MO·I) and E cells 
(Ell. Stain ing for the "110 T - cell receptor (TC R-15J) was Olt 
background leveis. Urushio l T-cell lines d e pleted of D4 + cells by 
adhe re n ce to ami-CD4-coated flasks cOl1willed g reater tb Hn 95% 
CD8+ cell s and less than S'if. C D4 + cells. The expression of D 28 
on CD8+ jJurifie d c ulture d urushi o l-responsi ve T cell s was 90-
95')10. 
Allti-CD28 Reconstituted the AbHity of Para form. aldehyde_ 
Fixed APC to Presellt Urushiol to T Cells T h e abi li ty offixed 
A PC to present urushio l to IlLrman CD8 + uru shio l- responsive 
T-cel l lines was tested in pro life ra tion assays (Fig 1). APC (amol_ 
ogo lls VBMC) were pre-in c ubate d 1 h with urus h io l (1 J..Lg pe r ml) 
and e ither irrildiatcd 6,000 R o r· tlxed w ith panlfo rmaldch yd e a 
describe d . Con trol APe w e re not exposed to urushio l. A.nd-C D 2 
ascites (1 :50U d ilu tion) w;rs added to til e proli feratio n ass;IY a 
indi cated. eH.l T h ymidine was added ilt 24 h, an d the ce lls w ere 
harvested 18 h later. 
Urushio l- responsive T - cel l lines proliferMed in respo nse to irra-
diated APC t hat had been pre- inc ubated with tlnlshio l; however, 
APC pre-inc ubated with llrlls iliol and tlxed with p;lrafOl"llla ld e h yd e 
elicited e ither ;1 g rea tl y d imin ished o r no respo nse. T his defect it) 
antige n presell tMio n .wa s reconstitute d by the addition or anti-
CD28. Figure 1 illu strates data li·orn tWO sllc h ex.pe rimenr 
pe rform ed. T hus, anti-CD28 wns a b le to act as a co-stiUlLI lato r for 
CDS+ urushio l- respons.iv e T-cell li nes in a 'nal1nc r simi.lar to chat 
reponed for CD4 + tet;1I1 11S toxoid-respo nsive lines (fen ldns el (//. 
199 1) . 1n additio ll al experim ents (not shown). sirnilar dar:1 w e r ' 
generate d with anti-CD28 ;lnd teta nus coxoid-responsive T - cell 
lin es , duplica ti n g pllblishe d re su lts. 
CD28 Blocking Agent CTLA4Ig B l ocJ(s Response ofCD8+ 
T Cells to Urushiol The C D28 bl ocking reagen t CTLA4l g 
(Lenshow el ai , ·1992; Schwartz , 1992) was used to dete rmine 
w hether the prolife ration or CD8 + T cell s ill respo nsc to urush iol 
was m edi;ltcd by CD28 co-s t imub tiol1 . CD8 + urushiol-reactive 
c ultured T cells (5 .0 X ·IO ' ce lls per 1111) were add >d to irradiate.d 
autologolls pnMC (1 X ·1 O('celh pe r (111) alo n g with u rush.io l (1 In'''' 
per 1111) and CTLA4[g at con centration s v'lIy ing fi-om O.S J.1-g per I11l 
to 4 J..Lg per ml in a tota l volul1w of 0. 2 111 1 pcr well. CTLA41g was 
present for the e ntire proli fe ration ass'ly. Proliferation W~~ deter-
mine d br eH)tbymid ine up take as above. Maximum [" 1:iJthYl11i-
d in e u jJt<1ke was d e termin ed by the CD8 + ee ll response to urushiol 
and irr:ldiaccd pnMC in th e abse nce of C TLA41g. Background 
er-l] thymidine up take wag determined by t lte response to irradiated 
PBMC in the absence o f u rushiol. CTLA4tg W;l$ ab.1e to bl ock the 
proliCeration. of CD8 + cells to urus hio l (Table I), indi cating tha r 
VOL. 108, NO.3 MARCI-I 1997 CD8 TOLERAN E 255
Table 1. CTLA4Ig Blocking of CD8+ Cell Proliferation
to Urushiol"
Figure 1. Anti-CD28 reconstituted the ability of paraformalde-
hyde fixed antigen presenting ceUs to present urushiol to CD8+
T -cells. PUMC were pre-incubated with urushiol as indicated and irradi-
ated (6.0001'.) or fixed with 0.'1 2'){, parafonTwldehyde. Anti-CD28 ascites
(1:500) was added as indicated. Microtiter wells were pulsed with eHlthy-
midine at 24 hand harvested IS h later. A and 13 indicate 2 independent
experiments with different CD8+ T-cell lines (Mean:':: SEM).
S. I."Assa)'
Mean:':: SEM
ProliferationAntigen
7 Da)' Pre-incubation
APC
1A Fix P13MC None APC 12505' ± 3636 Reference
18 Fix PBM None APC + mushiol 44324 :±:: 2508 3.55
1C Fix PHM None IL-2 20 U/ml 42643 :':: 2433 3.41
2A Fix PBMC Urushiol APC 7526 ± 843 Reference
28 Fix PBMC Urushiol APC + urushiol 8407 ± 1508 1.12
2 Fix PHMC Urush.iol lL-2 20 U/ml 28287:':: 2418 3.76
"CDt3+ urushiol-specific T cells were prc:-incllbated for 7 d with par;lforllwldc-
hyde-fixed PBM . Urushiol Wt\$ ::Idded to the pre-incubation as indic:ll"cd. CD8+ cells
were rhcll added to a prolifcr;ltioll :lssay with fresh irr:ldiatcd PBMC .IS APe, and either
rnediullI ;llonc, urushiol, or 11-2 (20 U/ml) as: indicated,
It Stimulation index, calculated as cxpCrilllCl1taJ dpm/rercrencc dplll,
(' 1,11-1lThYl11idillc upt;lkc ill dpm.
fore predicted that incub'ltion of T cells with fixed PBMC plus
antigen would induce anergy (Table II). CD8+ cells werc cultured
for 7 d along with APC in the presence or absence of urushiol. Both
fixed PBMC and irradiated PBMC were used as APC. Medium for
incubation contained 5 U of IL-2 per ml. Mter 7 d of incubation,
the CD8+ ceUs were washed and counted with trypan blue for
viabil.ity. CD8+ cells were then added to a prol.iferation assay along
with fresh irradiated autologous PBMC as APC. The variables for
the proliferation assay were; A: APC without antigen; B: APC plus
urushiol; and C: IL-2, 20 U per ml (viability control).
Pre-i.ncubation of urushiol-specific CD8+ T ceIJs with fixed
PBMC plus urushiol induced anergy as measured by inability to
proliferate to urushiol (Fig 2A). These anergic cells were viable,
however, and were capable ofprol.iferation in response to 1L-2 (Fig
2B). As predicted, pre-incubation with fixed PBMC in the absence
of urushiol did not induce anergy, nor did incubation with irradi-
ated PBMC + urushiol, which resulted in an accentuated response
to lL-2, suggesting that the T -ceIJ.s had been stimulated during the
7-d incubation. Anergy induction was antigen specific. as it was not
observed following pre-incubation of urushiol-specific CD8 + cells
.vith tetanus toxoid (Fig 2A).
DISCUSSION
Table ll. Induction of Anergy of CD8+ Urushiol-
Specific T Cells"
Anti-CD28 was able to provide a necessary co-stimulation signal
for urushiol-specific CD8+ cells. Co-stimulation of these CD8+ T
ceUs with anti-CD28 induced urushiol-specific proliferation. Pro-
liferation of CD8+ urushiol reactive T-cells was blocked by
CTLA4Ig, a recombinant molecule k.nown to block the interaction
of B7 molecules with human T cell CD28 (Schwa.rtz, 1992).
Hapten-specific CD8+ cells also required CD28 co-stimulation.
Pre-incubation of CD8+ urushiol-specific cells with fixed PBMC
+ urushiol induced anergy to urushiol. The CD8+ ceUs were
viable as measured by ability to proliferate to IL-2. Induction of
'lI1ergy to urushiol was antigen specific, because it could not be
induced by pre-incubation with tetanus toxoid. Ancrgy was not
induced by pre-incubation with ilTadiated PBMC, which were
capable of transmitting a complete activation signal. It is proposed
that lack of the B7 signal is one factor in the induction of anergy.
Anergy induction of CD4 + ceUs mediated by blocking of CD28
interactions has been well described. Anergic CD4+ ceUs have a
block in T-cell activation prior to activ;ltion of the ER.K-1, ERK-2
kinases, and ras (Fields ef ai, 1996; Li et ai, t 996). This block .in ras
activation inhibits the transcription f.'lctor AP-1., th >reby preventing
IL-2 production. The anergic cells retain the abil.ity to proliferate to
lL-2 and produce y-interferon.
B7-1 (CD80) and B7-2 (CD86) are members of the immullo-
globulin superfamily, coded by linked genes on human chromo-
some 3q13-q26 (Femandez-Ruiz e/ ai, 1995). Both molecules
interact with CD28 and CTLA4, and B7-1 binds CD28 and
CTLA4 at the same site (Guo et ai, 1995). There is evidence,
however, that B7-1 and B7-2 may induce differellt responses fi'om
0.8:':: 0.1
31.9 ± 2.2
6.9 :'::1.3
7.3 ± 1.4
8.0 ± 3.5
4.7 ± 1.7
8.2 :':: 2.3
Exp 3
Mean:':: SEM
0.6:':: 0.3
28.J :':: 9.0
9.9 ± 5.9
9.7 :':: 3.1
15.4 :':: 0.7
10.9 :':: 5.3
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Exp 2
Mean:':: SEM
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6,OOOR APC+URUSHIOL
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CTLMI[;
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4.0 flg/1l11
3.0 flg/ml
2.0/.Lg/ml
·1.O/.Lg/llll
0.5/.Lg/ll1l
FIXED APC +antiCD28+URUSHIOL
A
B
CD28 co-stimulation was essential for the proliferation of human
hapten-specific CD8+ cells.
CTLA41g was tested for nonspecific toxic effects on T-celJ
proliferation. Urush.iol-spccific T cells (5 X 105ceIJs per 1111) were
incubated with lL-2 (20 U per ml), and concentrations ofCTLA4lg
ranging 6.·om 0.5 /Lg per ml to 4.0 /Lg per ml. After 24 h of
incubation, the cells were pulsed with eH]thymidine and harvested
18 h later. At no concentration of CTLA4fg was prol.iferation in
response to fL-2 inhibited (background eH] uptake for T cells +
medium dpm = 472; uptake for T cells + lL-2 20 U per 1111 dpm =
9,016). Human y-globulin (Sigma), did not inhibit proliferation of
urushiol-specific T cells to urushiol at concentrations varying fi:om
0.5 /Lg per ml to 4.0 mg per ml (data not shown).
Induction of Anergy of CD8+ Urushiol-Specific Human T
Cells Fixed PBMC did not provide co-stimulation. It was there-
FIXED APC + antiCD2B + URUSHIOL
n CH]Th)'ltlidinc uptnke ill dpm X 10-·' (N = (, wells),
None
fl[;1 III I
/l.gl III I
/.Lg/ll1!
fl[;/lll!
flg/ml
flg/ml
Urushiol
Figure 2. Response of urushiol specific T-cells to urushiol and
IL-2. (A) Response to urushiol following 7 day incubation with antigen
presenting ceUs in 'the presence or absence of urushiol as shown. (B)
Response co IL-2 under similar conditions (Mean :!: SEM). Urushiol
response is shown after subtraction of background response to APC without
antigen.
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injection of antigen or hapten plus inhibitors of B7/CD28 interac-
tion (e.g., CTLA4Ig).
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T cells. Both molecules bind CD28 with similar avidities, but £7-1
has a higher affinity for CTLA4 than does B7-2 (Linsley et ai, 1994).
There is evidence that CTLA4 has a negative effect on T-cell
proliferation (Waterhouse et ai, 1995). The current theory is that
B7-1 co-stimulation favors a THl response, and £7-2 co-stimula-
tion favors a TH2 response (Freeman et ai, 1995).
In the epidermis, B7 is expressed by Lmgerhans cells (Symington
et ai, 1993), but not by resting keratinocytes (Simon et ai, 1994).
Presentation of hapten or antigen by B7 negative APC may lead to
anergy. Keratinocytes in inflamed skin, however, are capable of
expressing a "B7-like molecule." This B7 expression has been
detected in conditions associated with a dense inflammatory infil-
trate, including allergic contact dermatitis and lichen planus (Simon
et ai, 1994). Keratinocytes also express ICAM-l under these
conditions (Grifl:iths et ai, 1989), which should facilitate interactions
with T cells. ICAM-l + DR+ keratinocytes are capable ofinducing
proliferation of human T cells in the presence of superantigens
(Strange et ai, 1994). B7+ keratinocytes also induce T-cell prolif-
eration to aHoantigen (Gaspari et ai, 1993). It is possible that
keratinocytes &om inflamed skin expressing ICAM-l and B7 could
present hapten to CD8+ T cells. Transgenic mice with B7-1
expression targeted to the epidermis do not express spontaneous
inflammation, but allergic contact responses are "exaggerated and
persistent" (Nasir et ai, 1994; WilJjams et ai, 1994).
CD28 co-stimulation appears essential for proliferation of hap-
ten-specific CD8+ T ceUs. The requirement for CD28 co-stimu-
lation was demonstrated by stimulation with anti-CD28 and block-
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